• 名称: ADCP Bioassay Effector Cell FcγRIIa (R variant) -NFAT/Jurkat
  • 货号: CBP74004
  • 浏览次数: 630
  • 已销售数量:0件
  • 评论信息
  • 购买数量:  购买数量不能低于最少订购数量!

购买 询价 收藏 QQ交流 好友推荐

 

CBP74004
I. Background

Antibody-dependent cell-mediated phagocytosis (ADCP) is one of the important mechanisms of action for antibody drug development. FcγRIIa is the predominant Fcγ receptor involved in the ADCP process. FcγRIIa is expressed in myeloid effector cells, including macrophages and neutrophils, where it plays a role in the activation of these effector cells. Several clinical studies have studied the correlation of a FcγRIIa polymorphism (R131H) and the response to IgG1 subclass monoclonal antibodies (mAbs) such as rituximab. Engineered amino-acid substitutions in Fc-mAbs have been developed to enhance the mAb-mediated phagocytosis of tumor cells by macrophages.

 
II. Description

Recombinant Jurkat T cell expressing a firefly luciferase gene under the control of NFAT response elements with constitutive expression of human FcγRIIa, Histidine variant.

 
III. Introduction
Host Cell: Jurkat
Expressed gene: NFAT-Luc-FcγRIIa
Stability: 32 passages
Synonym(s): N/A
Freeze Medium: 90% FBS+10% DMSO
Culture Medium: 1640+10%FBS+800ug/ml hygromycin+1ug/ml puromycin
Storage: Immediately upon receipt, store in liquid nitrogen.
Application(s): Characterize the Fc effector function of antibodies.
 
IV. Description of Host Cell Line
Organism: Human
Tissue: Peripheral blood
Disease: Childhood T acute lymphoblastic leukemia
Morphology: Lymphoblast
Growth Properties: Suspension
 
Ⅴ. Representative Data

Figure 1.Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of  human FcγRIIa, Histidine variant.

 

 Figure 2:Detect Luciferase assay by Promega Bright-Glo Luciferase Assay System. ADCP Bioassay Effector Cell FcγRIIa (R variant) -NFAT/Jurkat cells were stimulated by FcγRIIa (R variant), the S/B was 29.3-fold.

 

 

关键词: